1stOncology™: Cancer Intelligence Service – Page 12366 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Three additional product patents in the US for HyNap-Dasa

On February 18, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) reported that the United States Patent and Trademark Office (USPTO) has granted Xspray three new US patent for HyNap-Dasa (Press release, Xspray, FEB 18, 2020, View Source [SID1234649567]). The new patents, US10,561,643; US 10,561,644; and US10,561,645, are valid until January 2033. This means that Xspray now has seven product patents for the pharmaceutical composition of the company’s primary product candidate, HyNap-Dasa, in the company’s main market USA.
"With a total of seven patents for HyNap-Dasa in our most important market, we can justifiably state that it will be extremely difficult for other players to launch a dasatinib product based on amorphous solid dispersion in the United States during the lifetime of the patent, ie until January 2033. This is undoubtably very important for our potential partners," says Per Andersson, CEO of Xspray.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Xspray strives to obtain patents for both composition and technology and these new patents claim an amorphous solid dispersion (pharmaceutical composition) of dasatinib.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

On February 18, 2020 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that President and CEO Athena Countouriotis, M.D., will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Feb. 27 in New York and the Cowen 40th Annual Healthcare Conference on March 2 in Boston (Press release, Turning Point Therapeutics, FEB 18, 2020, View Source [SID1234564379]).

Dr. Countouriotis is scheduled to participate in a question and answer session at 10:30 a.m. ET at the SVB Leerink conference, and present a company overview at 2:50 p.m. ET at the Cowen conference. Both sessions will be accessible via audio webcast through the Investors page of www.tptherapeutics.com.

Entry into a Material Definitive Agreement

On February 18, 2020, Agenus Inc. (the "Company") reported that it has entered into an amendment (the "Amendment") with certain existing investors, pursuant to which the Company (Filing, 8-K, Agenus, FEB 18, 2020, View Source [SID1234554660]):

extended the maturity date of the $14.0 million senior subordinated promissory notes previously issued in 2015 (the "2015 Notes") by three years from February 20, 2020 to February 20, 2023;

extended the exercise period of the warrants to purchase 1,400,000 shares of the Company’s common stock previously issued in 2015 by three years from February 20, 2020 to February 20, 2023; and

issued new warrants to purchase 675,000 shares of the Company’s common stock with a term of five years and an exercise price of $4.48 per share, which represented a 20% premium over the 30-day average trailing closing price of the Company’s common stock (the "New Warrants").

A brief description of the terms and conditions of the 2015 Notes can be found in Item 2.03 of the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 26, 2015 and such brief description is incorporated by reference herein.

The securities issued in connection with the Amendment were issued in reliance on the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"). Neither the New Warrants nor the underlying shares of common stock have been registered under the Securities Act. Neither the New Warrants nor such underlying shares of common stock may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. No commission or other remuneration was paid or given directly or indirectly for soliciting such issuance.

Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020

On February 18, 2020 Gilead Sciences, Inc. (Nasdaq: GILD) reported that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2 at 12:00 p.m. Eastern Time (Press release, Gilead Sciences, FEB 18, 2020, http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-present-cowen-and-company-40th-annual-health [SID1234554511]).

The live webcast can be accessed at the company’s investors page at View Source Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.

Cytokinetics to Announce Fourth Quarter Results on March 3, 2020

On February 18, 2020 Cytokinetics, Incorporated (Nasdaq: CYTK) reported that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future (Press release, Cytokinetics, FEB 18, 2020, View Source [SID1234554510]).

The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 8698309.

An archived replay of the webcast will be available via Cytokinetics’ website until March 10, 2020. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 8698309 from March 3, 2020 at 7:30 PM Eastern Time until March 10, 2020.